NCT05929651View on ClinicalTrials.gov

Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 7, 2023

Primary Completion Date

September 9, 2024

Study Completion Date

September 9, 2024

Conditions

Meningococcal ImmunisationHealthy Volunteers

Interventions

BIOLOGICAL

MenACYW conjugate vaccine

Pharmaceutical form: Liquid solution Route of administration: Intramuscular (IM) injection

Trial Locations (2)

1430

Investigational Site Number : 0320002, Buenos Aires

C1425EFD

Investigational Site Number : 0320001, Ciudad Autonoma Buenos Aires

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy | Biotech Hunter | Biotech Hunter